Abstract P1-09-32: A Novel Candidate for Chemotherapy-Induced Alopecia Through Local Modulation of Apoptosis and Inflammation

In 2015, a study was conducted to investigate a new treatment for chemotherapy-induced alopecia (CIA), a distressing side effect of cancer therapies affecting 65% of patients. The study involved three parts. In the first part, 20 male subjects with androgenetic alopecia (AGA) had their Bcl-2 levels analyzed after 3 months of topical application of the treatment. The results showed that the treatment restored Bcl-2 levels towards normal. In the second part, the anti-inflammatory potential of the treatment was tested in vitro, showing that it could inhibit the expression of inflammatory markers in endothelial cells. In the third part, the treatment was applied topically to 11 female cancer patients, showing promising results in faster, non-patchy, original-quality recovery and prevention of CIA. The study concluded that the treatment normalized scalp apoptosis and attenuated scalp inflammation, key factors in preventing CIA and promoting hair recovery.